Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
The Australia diabetes care drugs and devices market covers insulins, glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, metformin and other oral agents, together with glucose monitors, sensors, insulin pens and pumps used to manage type 1, type 2 and gestational diabetes. Medicines are reimbursed mainly through the Pharmaceutical Benefits Scheme, while monitoring and delivery consumables are subsidised through the National Diabetes Services Scheme.
In 2025, the market is valued at AUD 3.10 billion and is forecast to grow at a CAGR of 6.10%, reaching AUD 5.60 billion by 2035. Growth is driven by 1,516,661 people registered with the National Diabetes Services Scheme in 2024-25, a general PBS co-payment cut to AUD 25, and wider access to continuous glucose monitoring.
Compound Annual Growth Rate
6.1%
Value in AUD billion
2026-2035
The Australia diabetes care drugs and devices market is changing from a market built on older insulins and metformin into one led by incretin therapies, cardiometabolic oral agents and connected glucose technology. Reimbursement decisions, rather than clinical availability alone, now decide which products reach patients.
Three forces are shaping the market: Pharmaceutical Benefits Scheme listings and price rules, patent expiries that open the way for generic dapagliflozin from October 2027, and subsidised sensors and pumps for people with type 1 diabetes.
In January 2026 the general PBS co-payment fell to AUD 25, in April 2026 Eli Lilly declined to list Mounjaro on the PBS despite a positive committee recommendation, and in August 2026 Diabetes Australia was named administrator of the Commonwealth Insulin Pump Program.
The market is moving from volume-led generic therapy towards higher-value incretin medicines, cardiometabolic oral agents and connected glucose technology. GLP-1 receptor agonists lead because semaglutide dominates PBS spending, while diabetes devices advance fastest as sensors and pumps reach every person with type 1 diabetes. Type 2 diabetes remains the largest patient group, and Type 1 diabetes grows quickest on technology funding. New South Wales remains the largest base, and Queensland grows fastest. PBS reform, patent expiries and device subsidies underpin a durable, multi-year outlook rather than a cyclical uplift.
| Metric | Value |
| Market Size 2025 | AUD 3.10 billion |
| Projected Market Size 2035 | AUD 5.60 billion |
| CAGR 2026 to 2035 | 6.10% |
| Fastest-Growing Product Type | Diabetes Devices: 8.2% CAGR |
| Fastest-Growing Diabetes Type | Type 1 Diabetes: 7.4% CAGR |
| Largest Revenue Segment 2025 | GLP-1 Receptor Agonists |
| Dominant State | New South Wales |
| Highest CAGR by State | Queensland: 6.8% |
| National Diabetes Services Scheme registrants 2024-25 | 1,516,661 people |
PBS Reimbursement Anchors Medicine Demand
Revenue is on course to expand by about 81% across the decade, from AUD 3.10 billion in 2025 to AUD 5.60 billion in 2035 at a 6.1% CAGR. Chronic, lifelong prescribing makes demand recurring, while the AUD 25 co-payment from January 2026 lowers the cost barrier for general patients.
Devices and Type 1 Technology Lead Growth
GLP-1 receptor agonists hold the largest revenue share, but diabetes devices grow at an estimated 8.2% CAGR and Type 1 Diabetes at an estimated 7.4% CAGR through 2035. Sensor upgrades on the National Diabetes Services Scheme and pump funding for young people show how technology spending is widening.
Mounjaro Decision Shapes Private Spending
Eli Lilly declined PBS listing in April 2026 after the committee recommended tirzepatide in March 2026 for type 2 diabetes. Patients therefore pay privately, which lifts out-of-pocket spending and keeps the question of a revised proposal open.
| Report Summary | Unit | Value |
| Base Year | AUD billion | 2025 |
| Historical Period | AUD billion | 2019 to 2025 |
| Forecast Period | AUD billion | 2026 to 2035 |
| Market Size 2025 | AUD billion | 3.10 |
| Market Size 2035 | AUD billion | 5.60 |
| CAGR 2026 to 2035 | Percentage | 6.10 % |
| CAGR by Product Type: Diabetes Devices | Percentage | 8.2 % |
| CAGR by Diabetes Type: Type 1 Diabetes | Percentage | 7.4 % |
| CAGR by Funding Pathway: Private Purchase | Percentage | 8.8 % |
| CAGR by State: Queensland | Percentage | 6.8 % |
| PBS Total Cost of Semaglutide 2024-25 | AUD Million | 379.39 |
| NDSS Product Expenditure 2024-25 | AUD Million | 346 |
| Market Share by State 2025 | New South Wales | Dominant Share |
The shift is structural, not cyclical. Reimbursement reform, incretin therapy and funded glucose technology are changing diabetes treatment, and subsidy design now matters as much as clinical evidence.
The Australia diabetes care drugs and devices market is being reshaped by subsidised sensors and pumps, cardiometabolic listings and lower patient co-payments.
October 2026 - FreeStyle Libre 3 Plus Reaches Everyone With Type 1 Diabetes
August 2026 - Diabetes Australia Takes Over Commonwealth Insulin Pump Program
May 2026 - Dapagliflozin Gains PBS Listing for Heart Failure
January 2026 - General PBS Co-Payment Falls to AUD 25
Policy and technology now move together. Lower co-payments, cardiometabolic listings and wider sensor and pump funding reinforce one another, keeping diabetes care central to Australian health spending.
Recent developments, presented from the most recent, show the market moving from reimbursement decisions into supply changes and patent disputes.
September 2026 - Wegovy Revised Submission Heads to November PBAC Meeting
July 2026 - Abbott Moves NDSS Users to FreeStyle Libre 2 Plus
April 2026 - Eli Lilly Declines Mounjaro PBS Listing for Type 2 Diabetes
February 2026 - Court Blocks Generic Dapagliflozin Listing Pending Trial
Reimbursement and intellectual property, not clinical access alone, decide market timing. The Mounjaro decision and the dapagliflozin injunction show how pricing and patents shape when new volumes reach patients.
The Expert Market Research’s report on the Australia Diabetes Care Drugs And Devices Market offers a detailed analysis of the market based on the following segments.
Market Breakup by Product Type
GLP-1 Receptor Agonists lead because semaglutide cost AUD 379.4 million in total across the PBS in 2024-25, and the committee recommended tirzepatide in March 2026. Diabetes Devices grow fastest at an estimated 8.2% CAGR through 2035, helped by the FreeStyle Libre 3 Plus rollout from October 2026. Insulins face portfolio change as Novo Nordisk retires Levemir and some Penfill cartridges by December 2026. SGLT2 Inhibitors gained a heart failure listing for dapagliflozin on 1 May 2026, while DPP-4 Inhibitors rely on linagliptin at AUD 52.1 million in 2024-25. Others cover metformin and sulfonylureas.
Market Breakup by Diabetes Type
Type 2 Diabetes leads because it makes up the great majority of cases among the 1.3 million adults with diabetes in 2022-24, and the PBS co-payment fell to AUD 25 in January 2026. Type 1 Diabetes grows fastest at an estimated 7.4% CAGR through 2035, as MiniMed raised about USD 560 million in a March 2026 flotation and the Insulin Pump Program passed to Diabetes Australia in August 2026. Gestational Diabetes was a stated priority for Diabetes Victoria in May 2025. Others cover monogenic and secondary forms of diabetes, and a University of Sydney study of April 2025 suggested undiagnosed cases add to demand.
Market Breakup by Funding Pathway
PBS-Subsidised Medicines lead, with empagliflozin at AUD 130.3 million and dapagliflozin at AUD 109.8 million in 2024-25 alongside semaglutide. Private Purchase grows fastest at an estimated 8.8% CAGR through 2035, because Mounjaro remains available through private purchase only after Eli Lilly declined listing in April 2026. NDSS-Subsidised Products reached AUD 346 million in 2024-25 through more than 5,800 access points, mainly community pharmacies, and Abbott moved users to Libre 2 Plus in July 2026. Public Hospital Supply covers inpatient insulin and pump initiation. Others include workplace and aged care supply.
Market Breakup by Region
New South Wales dominates as the most populous state and grows at an estimated 5.8% CAGR through 2035, with a mobile diabetes clinic launched in the Hunter and New England area in August 2025. Queensland is the fastest-growing state at an estimated 6.8%, supported by pharmacist chronic condition pilots described in July 2025 and Health and Wellbeing Queensland programs in November 2025. Victoria grows at an estimated 6.0%, with nearly 400,000 residents living with diabetes. Western Australia, at 6.5%, saw a AUD 10.4 million Diabetes Connect pledge in February 2025. South Australia grows at 5.9%, and Others, including Tasmania, the ACT and the Northern Territory, at 6.2%.
| CAGR 2026 to 2035, Market by State | Growth Rate |
| New South Wales | 5.8 % |
| Victoria | 6.0 % |
| Queensland | 6.8 % |
| Western Australia | 6.5 % |
| South Australia | 5.9 % |
| Others (incl. Tasmania) | 6.2 % |
Competition combines global incretin and insulin innovators, originator makers of cardiometabolic oral agents and device specialists. Entry barriers include PBS price negotiations, patent protection, supply security and the clinician relationships that anchor multi-year prescribing.
Novo Nordisk
Novo Nordisk, headquartered in Bagsværd, Denmark, was formed in 1989 through the merger of Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium, and sells insulins and semaglutide under the Ozempic and Wegovy brands. The Therapeutic Goods Administration removed Ozempic from its shortage list on 18 July 2025, and semaglutide cost the PBS AUD 379.4 million in 2024-25. A revised Wegovy submission for adults with cardiovascular disease and obesity goes to the November 2026 committee meeting.
Eli Lilly
Eli Lilly and Company, headquartered in Indianapolis, Indiana, was founded in 1876 by Eli Lilly and sells Mounjaro (tirzepatide), Trulicity, Humalog and Humulin. It confirmed the end of Mounjaro vial supply in favour of the KwikPen in June 2025, then declined PBS listing for type 2 diabetes on 24 April 2026 after the March 2026 recommendation. Private purchase is therefore the only route for Mounjaro, which keeps its Australian revenue exposed to patient price sensitivity.
AstraZeneca
AstraZeneca, headquartered in Cambridge, England, was formed on 6 April 1999 through the merger of Astra AB and Zeneca, and its Australian diabetes portfolio centres on Forxiga (dapagliflozin) and Xigduo. Dapagliflozin cost the PBS AUD 109.8 million in 2024-25, and the Federal Court granted an injunction on 16 February 2026 against Pharmacor's planned generic listing. A new PBS listing for heart failure with preserved ejection fraction began on 1 May 2026, supporting volume before the patent expires in October 2027.
Boehringer Ingelheim
Boehringer Ingelheim, headquartered in Ingelheim am Rhein, Germany, was founded in 1885 by Albert Boehringer and sells Jardiance (empagliflozin) and Trajenta (linagliptin) in Australia. Jardiance cost the PBS AUD 130.3 million and Trajenta AUD 52.1 million in 2024-25. A chronic kidney disease listing for empagliflozin took effect on 1 November 2025, and the co-payment cut of January 2026 applies to empagliflozin, and together these changes widen cardiometabolic use beyond glucose control.
Other players operating in the Australia diabetes care drugs and devices market include Sanofi, MSD, Abbott, Dexcom, and Medtronic, alongside generic insulin and metformin suppliers, community pharmacy chains, wholesalers and sensor and pump distributors supporting diabetes care across Australian states and territories.
Competition rests on reimbursement access, patent position, supply security and clinician trust rather than price alone, with incretin, SGLT2 and insulin leaders alongside device specialists.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
The Australia diabetes care drugs and devices market is valued at AUD 3.10 billion in 2025, supported by PBS reimbursement, rising diabetes prevalence and expanding subsidies for glucose monitoring and pumps, with New South Wales as the largest state.
The market is forecast to reach AUD 5.60 billion by 2035, growing at a CAGR of 6.10 % over the 2026 to 2035 period, driven by incretin and SGLT2 prescribing, a lower PBS co-payment and wider funding for sensors and insulin pumps.
Diabetes Devices records the highest CAGR at an estimated 8.2% through 2035, as subsidised sensors and the Insulin Pump Program extend technology access for people with type 1 diabetes.
New South Wales dominates as the most populous state. Queensland is the fastest-growing state at an estimated 6.8% CAGR, helped by pharmacist chronic condition pilots and community prevention programs.
Key players include Novo Nordisk, Eli Lilly, AstraZeneca, Boehringer Ingelheim, Sanofi, MSD, Abbott, Dexcom, and Medtronic.
It is an Australian Government scheme that subsidises syringes, pump consumables, glucose monitoring products and test strips through more than 5,800 access points. It had 1,516,661 registrants in 2024-25 and spent AUD 346 million on products.
The committee recommended tirzepatide in March 2026, but Eli Lilly Australia declined to proceed on 24 April 2026, citing the proposed price and funding caps. The medicine therefore remains available through private purchase only.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Diabetes Type |
|
| Breakup by Funding Pathway |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
Datasheet
AUD 2,749
AUD 2,499
tax inclusive*
Single User License
AUD 3,849
AUD 3,499
tax inclusive*
Five User License
AUD 4,949
AUD 4,499
tax inclusive*
Corporate License
AUD 6,049
AUD 5,499
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Stay upgraded and grab opportunities by strategic insights
Stay informed and aware for a Market Leverage
Analyze pricing patterns with comprehensive trend analyses.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Elevate supply chain with collaboration
Contact Us for Further Information
Our specialized analysts will be available to answer all the pre-purchase and post-purchase queries regarding the report.
Our specialized analysts will be available to answer all the pre-purchase and post-purchase queries regarding the report.
Staying one step ahead of the market landscape with our in-depth research methods, integrating advanced analytics to drive precise and tangible outcomes.
Our expert analyst team offers a significant advantage over competitors, with extensive market insights into the latest trends, putting you strategically ahead.
We deliver a simplified yet extensive report, comprising in-depth industry insights and analytics tailored to your industry requirements.
We are happy to help you navigate through the services we offer and solve your queries.
Contact us